230 related articles for article (PubMed ID: 22195646)
1. Optimizing treatment for patients with metastatic renal cell carcinoma in the Central and Eastern European region.
Vrdoljak E; Ciuleanu T; Kharkevich G; Mardiak J; Mego M; Padrik P; Petruželka L; Purkalne G; Shparyk Y; Skrbinc B; Szczylik C; Torday L
Expert Opin Pharmacother; 2012 Feb; 13(2):159-74. PubMed ID: 22195646
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.
Vrdoljak E; Torday L; Szczylik C; Kharkevich G; Bavbek S; Sella A
Expert Opin Pharmacother; 2016; 17(1):93-104. PubMed ID: 26619144
[TBL] [Abstract][Full Text] [Related]
3. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.
Bray F; Lortet-Tieulent J; Znaor A; Brotons M; Poljak M; Arbyn M
Vaccine; 2013 Dec; 31 Suppl 7():H32-45. PubMed ID: 24332296
[TBL] [Abstract][Full Text] [Related]
4. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review.
Gupta K; Miller JD; Li JZ; Russell MW; Charbonneau C
Cancer Treat Rev; 2008 May; 34(3):193-205. PubMed ID: 18313224
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of adverse events in patients with metastatic renal cell carcinoma.
Hagiwara M; Borker R; Oster G
Clin Ther; 2013 Dec; 35(12):1955-1963.e2. PubMed ID: 24290735
[TBL] [Abstract][Full Text] [Related]
6. ICUD-EAU International Consultation on Kidney Cancer 2010: treatment of metastatic disease.
Patard JJ; Pignot G; Escudier B; Eisen T; Bex A; Sternberg C; Rini B; Roigas J; Choueiri T; Bukowski R; Motzer R; Kirkali Z; Mulders P; Bellmunt J
Eur Urol; 2011 Oct; 60(4):684-90. PubMed ID: 21704448
[TBL] [Abstract][Full Text] [Related]
7. Use of targeted therapies for advanced renal cell carcinoma in the Asia-Pacific region: opinion statement from China, Japan, Taiwan, Korea, and Australia.
Ye D; Eto M; Chung JS; Kimura G; Chang WC; Chang YH; Pang ST; Lee JL; Niu Y; Gurney H; Uemura H
Clin Genitourin Cancer; 2014 Aug; 12(4):225-33. PubMed ID: 24630778
[TBL] [Abstract][Full Text] [Related]
8. Systemic therapy for metastatic renal cell carcinoma in treatment naïve patients: a risk-based approach.
Bukowski RM
Expert Opin Pharmacother; 2010 Oct; 11(14):2351-62. PubMed ID: 20586712
[TBL] [Abstract][Full Text] [Related]
9. Impact of anti-angiogenic treatments on metastatic renal cell carcinoma.
Ainsworth NL; Lee JS; Eisen T
Expert Rev Anticancer Ther; 2009 Dec; 9(12):1793-805. PubMed ID: 19954291
[TBL] [Abstract][Full Text] [Related]
10. Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe.
Rencz F; Péntek M; Bortlik M; Zagorowicz E; Hlavaty T; Śliwczyński A; Diculescu MM; Kupcinskas L; Gecse KB; Gulácsi L; Lakatos PL
World J Gastroenterol; 2015 Feb; 21(6):1728-37. PubMed ID: 25684937
[TBL] [Abstract][Full Text] [Related]
11. Tuberculosis trends in eastern Europe and the former USSR.
Raviglione MC; Rieder HL; Styblo K; Khomenko AG; Esteves K; Kochi A
Tuber Lung Dis; 1994 Dec; 75(6):400-16. PubMed ID: 7718828
[TBL] [Abstract][Full Text] [Related]
12. Euroguidelines in Central and Eastern Europe (ECEE) conference and the Warsaw Declaration - a comprehensive meeting report.
Kowalska JD; Oprea C; de Witt S; Pozniak A; Gökengin D; Youle M; Lundgren JD; Horban A;
HIV Med; 2017 May; 18(5):370-375. PubMed ID: 27553526
[TBL] [Abstract][Full Text] [Related]
13. Current status of epilepsy health care for adult patients from central and eastern European Union countries--a survey of members of the Central Europe Epilepsy Experts Working Group.
Jędrzejczak J; Marusic P; Haldre S; Majkowska-Zwolińska B; Bojinova-Tchamova V; Mameniskiene R; Mindruta I; Ravnik IM; Szupera Z; Sykora P; Verzbickis A; Daniluk J
Seizure; 2013 Jul; 22(6):452-6. PubMed ID: 23528980
[TBL] [Abstract][Full Text] [Related]
14. Current systemic management of metastatic renal cell carcinoma - first line and second line therapy.
Wright I; Kapoor A
Curr Opin Support Palliat Care; 2011 Sep; 5(3):211-21. PubMed ID: 21725244
[TBL] [Abstract][Full Text] [Related]
15. Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
Oudard S; Elaidi RT
Cancer Treat Rev; 2012 Dec; 38(8):981-7. PubMed ID: 22289686
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
17. Current status of human papillomavirus vaccination implementation in central and eastern Europe.
Seme K; Maver PJ; Korać T; Canton A; Částková J; Dimitrov G; Filippova I; Hudecová H; Iljazović E; Kaić B; Kesić V; Kuprevičienė N; Laušević D; Molnár Z; Perevoščikovs J; Spaczyński M; Stefanova V; Učakar V; Poljak M
Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(1):21-5. PubMed ID: 23674181
[TBL] [Abstract][Full Text] [Related]
18. Sequential therapy in metastatic renal cell carcinoma: pre-clinical and clinical rationale for selecting a second- or subsequent-line therapy with a different mechanism of action.
González Larriba JL; Espinosa E; García Carbonero I; García-Donas J; López M; Meana A; Puente J; Bellmunt J
Cancer Metastasis Rev; 2012 Sep; 31 Suppl 1():S11-7. PubMed ID: 22674353
[TBL] [Abstract][Full Text] [Related]
19. Progression free survival of first line vascular endothelial growth factor-targeted therapy is an important prognostic parameter in patients with metastatic renal cell carcinoma.
Seidel C; Busch J; Weikert S; Steffens S; Fenner M; Ganser A; Grünwald V
Eur J Cancer; 2012 May; 48(7):1023-30. PubMed ID: 22436979
[TBL] [Abstract][Full Text] [Related]
20. New drug therapies for advanced renal cell carcinoma.
Gore ME; Harrison ML; Montes A
Expert Rev Anticancer Ther; 2007 Jan; 7(1):57-71. PubMed ID: 17187520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
